Geranylgeranylacetone Ameliorates Intestinal Radiation Toxicity by Preventing Endothelial Cell Dysfunction

Area of Science:

• Oncology
• Gastroenterology
• Radiotherapy Research

Background:

• Radiation therapy for cancer frequently causes intestinal toxicity.
• Endothelial cell dysfunction is a key factor in radiation-induced intestinal injury.
• Geranylgeranylacetone (GGA) is known for treating ulcers and gastritis.

Purpose of the Study:

• To investigate the protective effects of Geranylgeranylacetone (GGA) against radiation-induced intestinal damage in mice.
• To evaluate GGA's impact on vascular endothelial cell function and survival post-irradiation in vitro.

Main Methods:

• Assessed intestinal injury in irradiated mice treated with GGA, measuring crypt survival and villi length.
• Examined microvessel preservation in GGA-treated mice.
• In vitro studies evaluated endothelial cell proliferation, tube formation, wound healing, invasion, and migration after irradiation with and without GGA.
• Analyzed vascular endothelial growth factor (VEGF)/VEGF receptor 1 (VEGFR1)/endothelial nitric oxide synthase (eNOS) signaling and tumor necrosis factor-alpha (TNFα) expression.

Main Results:

• GGA treatment significantly improved intestinal injury markers and prolonged survival time in irradiated mice.
• Intestinal microvessels were better preserved in GGA-treated mice.
• GGA maintained endothelial cell function post-irradiation by preserving VEGF/VEGFR1/eNOS signaling and reducing TNFα expression, but did not prevent radiation-induced cell death.

Conclusions:

• Geranylgeranylacetone (GGA) demonstrates a protective effect against radiation-induced intestinal damage.
• GGA supports vascular endothelial cell function during radiation injury, highlighting its potential as a therapeutic agent.
• Further research into GGA's role in mitigating radiotherapy side effects is warranted.